GHENT, Belgium, 22 January 2012 - Ablynx [Euronext Brussels:
ABLX] issued the following statement today. On Friday January
20th at 16.30 C.E.T., De Tijd, a Belgian
newspaper, published online what was alleged to be a summary
of a full article relating to Ablynx, scheduled to appear in
print on Saturday January 21st. The online
summary contained a number of negative statements and
quotations apparently resulting from an interview with Dr
Edwin Moses, Chairman and CEO of Ablynx. These statements and
quotations were poorly translated or simply not reflective of
the interview that took place. Ablynx's stock price fell
almost 14% in about an hour and over 400,000 shares were
traded in total - two to three times the normal volume. A
number of investors that contacted Ablynx directly were
clearly completely misled by the summary article and assumed
that disappointing news had been announced. In fact, no
material new information had been provided during the
interview with De Tijd.
On Saturday January 21st, the full printed
article appeared in De Tijd. There are significant errors in
many of the quotations and statements in this full article
but it is more representative of the actual interview than
the online summary.
Dr Moses commented: "We have asked De Tijd to remove the
online summary from their website which they have done. The
full article is now available instead. To assist investors,
we are posting on the Ablynx website our English translation
of the De Tijd article which we have edited extensively to
correct what we believe are material factual errors in
statements or quotations. Ablynx has developed into one of
Europe's leading public biotechnology companies and it is
vital for us and all our stakeholders that the media report
our activities properly and accurately."
Ablynxis a biopharmaceutical company engaged in the discovery and development of Nanobodies ®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has over 25 programmes in the pipelineand seven Nanobodies in clinical development. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis, and has had a collaboration with Pfizer. The Company is headquartered in Ghent, Belgium and currently employs over 290 people. More information can be found on www.ablynx.com.
For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Marieke Vermeersch Investor Relations Manager t: +32 (0)9 262
00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward - looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
distribué par | Ce noodl a été diffusé par Ablynx NV et initialement mise en ligne sur le site http://www.ablynx.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-22 22:58:34 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
ABLYNX STATEMENT ON PRESS ARTICLE AND RELATED SHARE PRICE MOVEMENTS |